Analysts expect Evolent Health to report Q3 2026 revenue of $727.06 million and normalized EPS of $0.06, with the current stock price of $4.33 trading well below the average analyst price target of $5.96.
The primary focus for investors this quarter is the profitability of the company's Performance Suite and its ability to manage persistent medical cost inflation in oncology and cardiology.
While revenue is projected to grow over 50% year-over-year, investors remain cautious due to the company's high leverage, currently estimated at approximately 7x net debt-to-EBITDA.
Management's progress on margin recovery initiatives and stabilization of specialty care clinical costs will be critical for a stock that has faced significant pressure over the past year.